RBM20 mutations cause arrhythmogenic dilated cardiomyopathy via disturbed calcium handling, suggesting a potential therapeutic role for L-type calcium channel blockers.
We show that loss of Rbm20 disturbs Ca2+ handling and leads to more proarrhythmic Ca2+ releases from the sarcoplasmic reticulum. Patients that carry a pathogenic RBM20 mutation have more ventricular arrhythmias despite a similar left ventricular function, in comparison with patients with a TTN mutation. Our experimental data suggest that RBM20 mutation carriers may benefit from treatment with an ICa,L blocker to reduce their arrhythmia burden.
Hoogenhof et al. (Thu,) studied this question.